Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (7606)	10/31/1998 8:56:00 AM
From: Robert K.	Respond to of 17367

Thanks jackie. George>lbp.....>"these results prompted xoma to monitor the plasma levels of lbp in patients enrolled in clinical trials of bpi" >"plasma levels of lbp are significantly elevated in diseases involving exposure to endotoxin" Now I ask you if high levels of lbp are prognostic for poor outcome, then what would you do to attempt to alter outcome. Specifically, what does bpi do to cd14 (and lbp), and what does lbp do to bpi. AND what does a non-stimulatory (to cd14) lbp derivative accomplish in this context. Dont forget the endotoxin aspect either. Think bpi/lbp/cd14/cascade and cytokines. Soooooo, if you see high lbp levels and you know the patient is in trouble, how could you try to utilize bpi with this in mind. Conversely, if you have a patient with low lbp levels then what does THAT tell you? Really think on this. LBP levels target may target patients that"potentially"will benefit from bpi. And which patients again ARE those. Exposure to bacteria types. And who has high lbp levels? Abdominal infections,sepsis,meningo, and to a lesser degree crohns,colitis,cirrhosis, and even I think CF. Once you know your targets, then, you know your treatment. Will bpi work? Lets wait and see. All IMO. All disclaimers.